Inhibitors and antibody fragments as potential anti-inflammatory therapeutics targeting neutrophil proteinase 3 in human disease

Brice Korkmaz, Adam Lesner, Carla Guarino, Magdalena Wysocka, Christine Kellenberger, Hervé Watier, Ulrich Specks, Francis Gauthier, Dieter E. Jenne

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Proteinase 3 (PR3) has received great scientific attention after its identification as the essential antigenic target of antineutrophil cytoplasm antibodies in Wegener’s granulomatosis (now called granulomatosis with polyangiitis). Despite many structural and functional similarities between neutrophil elastase (NE) and PR3 during biosynthesis, storage, and extracellular release, unique properties and pathobiological functions have emerged from detailed studies in recent years. The development of highly sensitive substrates and inhibitors of human PR3 and the creation of PR3-selective single knockout mice led to the identification of nonredundant roles of PR3 in cell death induction via procaspase-3 activation in cell cultures and in mouse models. According to a study in knockout mice, PR3 shortens the lifespan of infiltrating neutrophils in tissues and accelerates the clearance of aged neutrophils in mice. Membrane exposure of active human PR3 on apoptotic neutrophils reprograms the response of macrophages to phagocytosed neutrophils, triggers secretion of proinflammatory cytokines, and undermines immune silencing and tissue regeneration. PR3-induced disruption of the anti-inflammatory effect of efferocytosis may be relevant for not only granulomatosis with polyangiitis but also for other autoimmune diseases with high neutrophil turnover. Inhibition of membrane-bound PR3 by endogenous inhibitors such as the α-1-protease inhibitor is comparatively weaker than that of NE, suggesting that the adverse effects of unopposed PR3 activity resurface earlier than those of NE in individuals with α-1-protease inhibitor deficiency. Effective coverage of PR3 by anti-inflammatory tools and simultaneous inhibition of both PR3 and NE should be most promising in the future.

Original languageEnglish (US)
Pages (from-to)603-630
Number of pages28
JournalPharmacological Reviews
Volume68
Issue number3
DOIs
StatePublished - Jun 1 2016

Fingerprint

Myeloblastin
Immunoglobulin Fragments
Anti-Inflammatory Agents
Leukocyte Elastase
Neutrophils
Granulomatosis with Polyangiitis
Therapeutics
Protease Inhibitors
Knockout Mice
Membranes
Phagocytosis
Caspase 3
Autoimmune Diseases
Regeneration

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Korkmaz, B., Lesner, A., Guarino, C., Wysocka, M., Kellenberger, C., Watier, H., ... Jenne, D. E. (2016). Inhibitors and antibody fragments as potential anti-inflammatory therapeutics targeting neutrophil proteinase 3 in human disease. Pharmacological Reviews, 68(3), 603-630. https://doi.org/10.1124/pr.115.012104

Inhibitors and antibody fragments as potential anti-inflammatory therapeutics targeting neutrophil proteinase 3 in human disease. / Korkmaz, Brice; Lesner, Adam; Guarino, Carla; Wysocka, Magdalena; Kellenberger, Christine; Watier, Hervé; Specks, Ulrich; Gauthier, Francis; Jenne, Dieter E.

In: Pharmacological Reviews, Vol. 68, No. 3, 01.06.2016, p. 603-630.

Research output: Contribution to journalArticle

Korkmaz, B, Lesner, A, Guarino, C, Wysocka, M, Kellenberger, C, Watier, H, Specks, U, Gauthier, F & Jenne, DE 2016, 'Inhibitors and antibody fragments as potential anti-inflammatory therapeutics targeting neutrophil proteinase 3 in human disease', Pharmacological Reviews, vol. 68, no. 3, pp. 603-630. https://doi.org/10.1124/pr.115.012104
Korkmaz, Brice ; Lesner, Adam ; Guarino, Carla ; Wysocka, Magdalena ; Kellenberger, Christine ; Watier, Hervé ; Specks, Ulrich ; Gauthier, Francis ; Jenne, Dieter E. / Inhibitors and antibody fragments as potential anti-inflammatory therapeutics targeting neutrophil proteinase 3 in human disease. In: Pharmacological Reviews. 2016 ; Vol. 68, No. 3. pp. 603-630.
@article{a554b8a03dc647c3a703eea0ec05401a,
title = "Inhibitors and antibody fragments as potential anti-inflammatory therapeutics targeting neutrophil proteinase 3 in human disease",
abstract = "Proteinase 3 (PR3) has received great scientific attention after its identification as the essential antigenic target of antineutrophil cytoplasm antibodies in Wegener’s granulomatosis (now called granulomatosis with polyangiitis). Despite many structural and functional similarities between neutrophil elastase (NE) and PR3 during biosynthesis, storage, and extracellular release, unique properties and pathobiological functions have emerged from detailed studies in recent years. The development of highly sensitive substrates and inhibitors of human PR3 and the creation of PR3-selective single knockout mice led to the identification of nonredundant roles of PR3 in cell death induction via procaspase-3 activation in cell cultures and in mouse models. According to a study in knockout mice, PR3 shortens the lifespan of infiltrating neutrophils in tissues and accelerates the clearance of aged neutrophils in mice. Membrane exposure of active human PR3 on apoptotic neutrophils reprograms the response of macrophages to phagocytosed neutrophils, triggers secretion of proinflammatory cytokines, and undermines immune silencing and tissue regeneration. PR3-induced disruption of the anti-inflammatory effect of efferocytosis may be relevant for not only granulomatosis with polyangiitis but also for other autoimmune diseases with high neutrophil turnover. Inhibition of membrane-bound PR3 by endogenous inhibitors such as the α-1-protease inhibitor is comparatively weaker than that of NE, suggesting that the adverse effects of unopposed PR3 activity resurface earlier than those of NE in individuals with α-1-protease inhibitor deficiency. Effective coverage of PR3 by anti-inflammatory tools and simultaneous inhibition of both PR3 and NE should be most promising in the future.",
author = "Brice Korkmaz and Adam Lesner and Carla Guarino and Magdalena Wysocka and Christine Kellenberger and Herv{\'e} Watier and Ulrich Specks and Francis Gauthier and Jenne, {Dieter E.}",
year = "2016",
month = "6",
day = "1",
doi = "10.1124/pr.115.012104",
language = "English (US)",
volume = "68",
pages = "603--630",
journal = "Pharmacological Reviews",
issn = "0031-6997",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Inhibitors and antibody fragments as potential anti-inflammatory therapeutics targeting neutrophil proteinase 3 in human disease

AU - Korkmaz, Brice

AU - Lesner, Adam

AU - Guarino, Carla

AU - Wysocka, Magdalena

AU - Kellenberger, Christine

AU - Watier, Hervé

AU - Specks, Ulrich

AU - Gauthier, Francis

AU - Jenne, Dieter E.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Proteinase 3 (PR3) has received great scientific attention after its identification as the essential antigenic target of antineutrophil cytoplasm antibodies in Wegener’s granulomatosis (now called granulomatosis with polyangiitis). Despite many structural and functional similarities between neutrophil elastase (NE) and PR3 during biosynthesis, storage, and extracellular release, unique properties and pathobiological functions have emerged from detailed studies in recent years. The development of highly sensitive substrates and inhibitors of human PR3 and the creation of PR3-selective single knockout mice led to the identification of nonredundant roles of PR3 in cell death induction via procaspase-3 activation in cell cultures and in mouse models. According to a study in knockout mice, PR3 shortens the lifespan of infiltrating neutrophils in tissues and accelerates the clearance of aged neutrophils in mice. Membrane exposure of active human PR3 on apoptotic neutrophils reprograms the response of macrophages to phagocytosed neutrophils, triggers secretion of proinflammatory cytokines, and undermines immune silencing and tissue regeneration. PR3-induced disruption of the anti-inflammatory effect of efferocytosis may be relevant for not only granulomatosis with polyangiitis but also for other autoimmune diseases with high neutrophil turnover. Inhibition of membrane-bound PR3 by endogenous inhibitors such as the α-1-protease inhibitor is comparatively weaker than that of NE, suggesting that the adverse effects of unopposed PR3 activity resurface earlier than those of NE in individuals with α-1-protease inhibitor deficiency. Effective coverage of PR3 by anti-inflammatory tools and simultaneous inhibition of both PR3 and NE should be most promising in the future.

AB - Proteinase 3 (PR3) has received great scientific attention after its identification as the essential antigenic target of antineutrophil cytoplasm antibodies in Wegener’s granulomatosis (now called granulomatosis with polyangiitis). Despite many structural and functional similarities between neutrophil elastase (NE) and PR3 during biosynthesis, storage, and extracellular release, unique properties and pathobiological functions have emerged from detailed studies in recent years. The development of highly sensitive substrates and inhibitors of human PR3 and the creation of PR3-selective single knockout mice led to the identification of nonredundant roles of PR3 in cell death induction via procaspase-3 activation in cell cultures and in mouse models. According to a study in knockout mice, PR3 shortens the lifespan of infiltrating neutrophils in tissues and accelerates the clearance of aged neutrophils in mice. Membrane exposure of active human PR3 on apoptotic neutrophils reprograms the response of macrophages to phagocytosed neutrophils, triggers secretion of proinflammatory cytokines, and undermines immune silencing and tissue regeneration. PR3-induced disruption of the anti-inflammatory effect of efferocytosis may be relevant for not only granulomatosis with polyangiitis but also for other autoimmune diseases with high neutrophil turnover. Inhibition of membrane-bound PR3 by endogenous inhibitors such as the α-1-protease inhibitor is comparatively weaker than that of NE, suggesting that the adverse effects of unopposed PR3 activity resurface earlier than those of NE in individuals with α-1-protease inhibitor deficiency. Effective coverage of PR3 by anti-inflammatory tools and simultaneous inhibition of both PR3 and NE should be most promising in the future.

UR - http://www.scopus.com/inward/record.url?scp=84975784387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975784387&partnerID=8YFLogxK

U2 - 10.1124/pr.115.012104

DO - 10.1124/pr.115.012104

M3 - Article

C2 - 27329045

AN - SCOPUS:84975784387

VL - 68

SP - 603

EP - 630

JO - Pharmacological Reviews

JF - Pharmacological Reviews

SN - 0031-6997

IS - 3

ER -